Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7814MR)

This product GTTS-WQ7814MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7814MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11084MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ4259MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ6882MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ2875MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ13080MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ4201MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ3644MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ10582MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3127804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW